
July 27, 2020 — QuartzBio’s Tobias Guennel, PhD, presented the following poster, “A Genetic Enrichment Strategy for Delay of Onset of Alzheimer’s Disease Clinical Trials,” at AAIC 2020.
Read moreJuly 27, 2020 — QuartzBio’s Tobias Guennel, PhD, presented the following poster, “A Genetic Enrichment Strategy for Delay of Onset of Alzheimer’s Disease Clinical Trials,” at AAIC 2020.
Read moreJuly 16, 2020 — Computational approaches using COVID-19 data can be invaluable in quickly generating insights for drug repurposing, target pathway selection, and many other challenges. In this webinar, QuartzBio’s Renee Deehan will discuss how teams are combining deep biological knowledge with computational and machine learning approaches.
The global pandemic caused by SARS-CoV-2 has resulted in an incredible mobilization of biopharma resources and attention.
Agile research groups are recognizing the valuable opportunity for computational approaches to accelerate paths to insight generation. Mechanistically-guided methods have significant potential to inform and expedite critical decisions that would have previously required time consuming and costly de novo research studies.
Join us to learn how teams are combining deep biological knowledge with computational and machine learning approaches.
You’ll see how high resolution modeling of COVID-19 and related conditions enables:
Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments. Precision for Medicine is part of Precision Medicine Group, with 3,000 employees in 40 locations.
QUARTZBIO® and the PRECISION QUARTZBIO® logo are registered trademarks of Precision Medicine Group, LLC in the United States and/or other jurisdictions. All rights reserved.
© 2024. All rights reserved.
Precision Medicine Group, LLC.
Privacy Policy | GDPR
Web Design and Development by RainCastle Communications.